Nutriband Inc. has partnered with Kindeva to develop AVERSA™ Fentanyl, a new abuse-deterrent transdermal fentanyl patch. This collaboration combines Nutriband’s AVERSA™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. The joint effort aims to improve the safety profile of fentanyl patches by incorporating agents that deter misuse, while ensuring continued access for patients in need of effective pain management.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604143) on December 18, 2025, and is solely responsible for the information contained therein.
Comments